Download in electronic PDF format for $25



Search the Complete Journal Archives

Stability and In Vitro Toxicity of an Infliximab Eye Drop Formulation

Author(s):  Robert Marie-Claude,Spurr-Michaud Sandra,Frenette Mathieu,Young David,Gipson Ilene K,Dohlman Claes H

Issue:  Sep/Oct 2014 - Volume 18, Number 5
View All Articles in Issue

Abstract:  The purpose of this study was to develop a novel 10-mg/mL infliximab eye drop, to characterize its physical and biological stability under recommended storage conditions, and to assess the formulation’s toxicity to ocular surface epithelium in vitro. Infliximab (10 mg/mL) was reconstituted using equal volumes of sterile water and 1% carboxymethylcellulose artificial tears. Aliquots were stored in either a 4oC refrigerator or -20oC freezer for up to 45 days. Physical stability was assessed through monitoring the solution’s appearance, pH, ultraviolet-visiblenear infrared absorbance and scattering, as well as protein gel electrophoresis. Biological stability was assayed through binding to tumor necrosis factor-alpha using an enzyme-linked immunosorbent assay. In vitro cytotoxicity to human corneal-limbal epithelial cells was examined following a 4-hour exposure to the study drug. Refrigerated and frozen infliximab eye drops remained clear and colorless for the duration of study. The formulation’s pH (7.0) was comparable to that of the artificial tear vehicle alone. Low levels of ultraviolet-visible-near infrared light absorbance and scattering established the lack of protein precipitate after refrigeration or freezing. Protein gel electrophoresis performed under reducing conditions revealed the presence of two main protein bands of approximately 50 kDa and 25 kDa, representing immunoglobulin G heavy and light chains. The migration pattern of the proteins did not change under the different storage conditions and between day 10 and 45 after formulation. Infliximab binding to tumor necrosis factor-alpha remained stable for up to 45 days, with conservation of 101% and 102% of its initial binding activity when refrigerated or frozen, respectively. In vitro human corneal-limbal epithelial cultures showed no increase in cytotoxicity with infliximab treatment when compared to vehicle and culture media controls (P > 0.05). Infliximab can be formulated as an eye drop and remains stable when stored in accordance with current regulations regarding compounded eye drops. The demonstrated physical and biological stability as well as in vitro innocuity of this infliximab eye drop formulation may facilitate future clinical investigation targeting tumor necrosis factor-alpha as a modulator of various ocular surface diseases.

Related Keywords: Marie-Claude Robert, MD, Sandra Spurr-Michaud, MS, Mathieu Frenette, PhD, David Young, RPh, Ilene K. Gipson, PhD, Claes H. Dohlman, MD, PhD, ocular surface diseases, eye disorders, tumor necrosis factor alpha, monoclonal immunoglobulin G antibody, uveitis, dry eye, topical preparations, eye drops, ocular administration

Related Categories: OPHTHALMICS, STABILITIES, COMPATIBILITIES, ADVERSE DRUG EVENTS, ALLERGY/IMMUNOLOGY/INFLAMMATION

Printer-Friendly Version

Related Articles from IJPC
Title (Click for Abstract / Details) Author Issue Page View/Buy
Stability and In Vitro Toxicity of an Infliximab Eye Drop Formulation Robert Marie-Claude, Spurr-Michaud Sandra, Frenette Mathieu, Young David, Gipson Ilene K, Dohlman Claes H Sep/Oct 2014 418-426 Buy
Infliximab 1% Ophthalmic Solution Allen Loyd V Jr Jan/Feb 2017 62 Buy
Autologous Eye Drops for the Treatment of Dry Eye and Neurotrophic Keratitis Mixon William, Angelle Patricea (Patsy), Chang Richard I Nov/Dec 2009 506-515 Buy
Protocol of Blood Serum Eye Drops Katsakoulas Ioannis, Lougovoi Claudia, Paraskevopoulou Penelope, Vougioukas Nikolaos May/Jun 2015 252-260 Buy
Autologous Serum Eye Drops for Severe Dry Eye Syndrome in a Patient with Chronic Graft-vs-Host Disease: A Case Report Mixon Bill, Mixon Jan, Isbey Edward K III, Sprinkle Shari Sep/Oct 2014 370-377 Buy
Rapid-Dissolve Technology: An Interview With Loyd V. Allen, Jr., PhD, RPh Allen Loyd V Jr Nov/Dec 2003 449-450 Buy
Testing the Long-Term Stability of Vancomycin Ophthalmic Solution McLellan Christine, Ngo Van, Pasedis Sophia, Dohlman Claes H Sep/Oct 2008 456-459 Buy
Quality-Control Analytical Methods: Applications and Sterility of Autologous Eye Drops Reed-Kane Dana, Carlson Rachel A, Kupiec Thomas C, Vu Nicole Nov/Dec 2009 540-543 Buy
Diverse Challenges in Pediatric Compounding: Treating Pulmonary Hypertension, Uncombable Hair Syndrome, and Acanthamoeba keratitis Muller George, Young Thomas W, Reina Rachel, Caldwell Delmar R Jan/Feb 2010 40-45 Buy
The Effects of Compounded Bioidentical Transdermal Hormone Therapy on Hemostatic, Inflammatory, and Immune Factors; Cardiovascular Biomarkers; Quality of Life Measures; and Health Outcomes in Perimenopausal and Postmenopausal Women Stephenson Kenna, Neuenschwander Pierre F, Kurdowska Anna K Jan/Feb 2013 74-85 View Sample